Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sanofi (SNY) EBITDA (2016 - 2025)

Historic EBITDA for Sanofi (SNY) over the last 17 years, with Q4 2025 value amounting to -$5.6 billion.

  • Sanofi's EBITDA fell 101203.3% to -$5.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.1 billion, marking a year-over-year decrease of 499.02%. This contributed to the annual value of $7.2 billion for FY2025, which is 866.02% down from last year.
  • As of Q4 2025, Sanofi's EBITDA stood at -$5.6 billion, which was down 101203.3% from $8.6 billion recorded in Q3 2025.
  • Sanofi's EBITDA's 5-year high stood at $10.9 billion during Q4 2022, with a 5-year trough of -$5.6 billion in Q4 2025.
  • For the 5-year period, Sanofi's EBITDA averaged around $2.9 billion, with its median value being $2.4 billion (2021).
  • In the last 5 years, Sanofi's EBITDA soared by 54474.37% in 2022 and then plummeted by 101203.3% in 2025.
  • Sanofi's EBITDA (Quarter) stood at $1.7 billion in 2021, then surged by 544.74% to $10.9 billion in 2022, then decreased by 22.06% to $8.5 billion in 2023, then plummeted by 92.77% to $612.3 million in 2024, then tumbled by 1012.03% to -$5.6 billion in 2025.
  • Its EBITDA was -$5.6 billion in Q4 2025, compared to $8.6 billion in Q3 2025 and $1.7 billion in Q2 2025.